Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients

5Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Upgrading and/or upstaging in low-risk prostate cancer (PCa) patients may represent an indication for active treatment instead of active surveillance (AS). We addressed contemporary upgrading and/or upstaging rates in a large population based-cohort of low-risk PCa patients. Materials and methods: Whitin the SEER database (2010–2015), NCCN low-risk PCa patients were identified across management modalities: radical prostatectomy (RP), radiotherapy (RT) and non-local treatment (NLT). In RP patients, upgrading and/or upstaging rates were assessed in logistic regression models. Results: Overall, of 27,901 low-risk PCa patients, 38% underwent RP vs 28% RT vs 34% NLT. RP patients were the youngest and harbored the highest percentage of positive cores and a higher rate of cT2a than NLT. At RP, 46.2% were upgraded to GGG ≥ 2, 6.0% to GGG ≥ 3 and 10.5% harbored nonorgan-confined stage (NOC, pT3-4 or pN1). Of NOC patients, 1.6% harbored GGG ≥ 3, 6.3% harbored GGG2 and 2.6% harbored GGG1. Of pT2 patients, 4.4% harbored GGG ≥ 3, 33.9% harbored GGG2 and 51.3% harbored GGG1. Age, PSA, percentage of positive cores and number of positive cores independently predicted the presence of NOC and/or GGG ≥ 3, but with low accuracy (63.9%). Conclusions: In low-risk PCa, critical changes between tumor grade and stage at biopsy vs RP may be expected in very few patients: NOC with GGG ≥ 3 in 1.6% and NOC with GGG2 in 6.3%. Other patients with upgrading and/or upstaging combinations will invariably harbor either pT2 or GGG1 that far less critically affect PCa prognosis.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Flammia, R. S., Hoeh, B., Hohenhorst, L., Sorce, G., Chierigo, F., Panunzio, A., … Karakiewicz, P. I. (2022). Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. International Urology and Nephrology, 54(10), 2521–2528. https://doi.org/10.1007/s11255-022-03250-0

Readers' Seniority

Tooltip

Researcher 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

50%

Biochemistry, Genetics and Molecular Bi... 1

25%

Veterinary Science and Veterinary Medic... 1

25%

Save time finding and organizing research with Mendeley

Sign up for free